全人源BCMA CAR-T(CT103A)治疗复发难治多发性骨髓瘤的1期研究
该1期研究评估了全人源BCMA特异性CAR-T(CT103A)在18例复发难治多发性骨髓瘤(RRMM)患者中的安全性和疗效,其中包括4例既往接受过鼠源BCMA CAR-T的患者。总缓解率为100%,72.2%达到完全缓解或严格完全缓解。CT103A安全性可控,且对既往鼠源BCMA CAR-T失败的患者仍可能有效。
要点
- CT103A在RRMM中总缓解率达100%,72.2%达完全缓解或严格完全缓解。
- 4例既往鼠源BCMA CAR-T暴露患者中,3例达严格完全缓解,1例达非常好的部分缓解。
- 最常见不良事件为血液学毒性,70.6%发生1-2级细胞因子释放综合征,未观察到ICANS。
核心结论
- CT103A在复发难治多发性骨髓瘤患者中安全且具有高活性,可作为有前景的治疗选择。
- 既往鼠源BCMA CAR-T治疗后复发的患者仍可能从CT103A中获益。
研究设计与样本
- 1期临床试验,纳入18例连续复发难治多发性骨髓瘤患者,其中4例既往接受过鼠源BCMA CAR-T。
- 剂量递增阶段给予1、3、6×10^6 CAR阳性T细胞/kg,扩展队列给予1×10^6 CAR阳性T细胞/kg。
主要发现
- 总缓解率为100%,72.2%的患者达到完全缓解或严格完全缓解。
- 4例既往鼠源BCMA CAR-T暴露患者中,3例达严格完全缓解,1例达非常好的部分缓解。
- 1年无进展生存率全体队列为58.3%,无髓外骨髓瘤患者为79.1%。
- 血液学毒性为最常见不良事件;70.6%的患者发生1或2级细胞因子释放综合征;未观察到免疫效应细胞相关神经毒性综合征。
- 截至 cutoff 日期,77.8%的患者可检测到CAR转基因;中位CAR转基因持续时间为307.5天;仅1例患者抗药抗体阳性。
临床怎么用
- CT103A可用于复发难治多发性骨髓瘤,包括既往鼠源BCMA CAR-T暴露的患者。
- 治疗中需重点监测血液学毒性和细胞因子释放综合征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non-human originated antigen-targeting domain may limit clinical efficacy, we developed a fully human BCMA-specific CAR, CT103A, and report its safety and efficacy in a phase 1 trial. Eighteen consecutive patients with RRMM, including 4 with prior murine BCMA CAR exposures, were enrolled. CT103A was administered at 1, 3, and 6 × 106 CAR-positive T cells/kg in the dose-escalation phase, and 1 × 106 CAR-positive T cells/kg in the expansion cohort. The overall response rate was 100%, with 72.2% of the patients achieving complete response or stringent complete response. For the 4 murine BCMA CAR-exposed patients, 3 achieved stringent complete response, and 1 achieved a very good partial response. At 1 year, the progression-free survival rate was 58.3% for all cohorts and 79.1% for the patients without extramedullary myeloma. Hematologic toxicities were the most common adverse events; 70.6% of the patients experienced grade 1 or 2 cytokine release syndromes. No immune effector cell-associated neurotoxicity syndrome was observed. To the cutoff date, CAR transgenes were detectable in 77.8% of the patients. The median CAR transgene persistence was 307.5 days. Only 1 patient was positive for the anti-drug antibody. Altogether, CT103A is safe and highly active in patients with RRMM and can be developed as a promising therapy for RRMM. Patients who relapsed from prior murine BCMA CAR T-cell therapy may still benefit from CT103A. This trial was registered at http://www.chictr.org.cn as #ChiCTR1800018137.
引用
- Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021. PMID: 33512480. doi:10.1182/blood.2020008936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。